Charles Flexner
MD
Johns Hopkins University School of Medicine, United States
International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021
Welcome
Monoclonal antibodies are a proven concept in the treatment of cancer and immune disorders, and their promise for both prevention and treatment of infectious diseases is being realized, too. Harnessing this technology has remarkably advanced therapeutic development for COVID-19, underscoring its utility and versatility to rapidly respond to emerging threats to global health or rethink the approach for conditions that are currently challenging to treat. Yet, upscaling the manufacturing process and the considerable price remain a challenge. Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, and recent clinical data. In contrast to existing programs that bring together experts within a specific field, the International Workshop Monoclonal Antibodies for HIV, COVID-19, and Oncology aimed to provide a platform for cross-talk of experts from different disciplines that will catalyze knowledge transfer and ultimately move the field forward.
Program Directors
Daniel Kuritzkes
MD
Brigham and Women's Hospital / Harvard Medical School, United States
General Information
Practical Information
We trust that the following information (in alphabetical order) will assist you in organizing your participation in the International Workshop Monoclonal Antibodies for HIV, COVID-19 and Oncology 2021.